Evidence map›Paper›PMID 24802970›Full record

ArticleCancer medicine2014

High CD49f expression is associated with osteosarcoma tumor progression: a study using patient-derived primary cell cultures.

Patrice Penfornis, David Z Cai, Michael R Harris, Ryan Walker, David Licini, Joseph D A Fernandes, Griffin Orr, Tejaswi Koganti, Chindo Hicks, Spandana Induru and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Pediatric sarcomas.Oncology letters · 2018
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Patrice PenfornisCancer Institute, University of Mississippi Medical Center, Jackson, Mississippi.
David Z Cai
Michael R Harris
Ryan Walker
David Licini
Joseph D A Fernandes
Griffin Orr
Tejaswi Koganti
Chindo Hicks
Spandana Induru
Mark S Meyer
Rama Khokha
Jennifer Barr
Radhika R Pochampally
University of Mississippi Medical Center · USTulane University · USCancer Institute (WIA) · IN

Funding

miRNA-mediated Stromal Cell Survival under Stress Supports Breast Cancer GrowthR01CA151851 · NCI · UNIVERSITY OF MISSISSIPPI MED CTR · PI POCHAMPALLY, RADHIKA R · 2011 to 2016
$1.5M
NCI NIH HHS CA151851NCI NIH HHS R01 CA151851
6 · The paper itself

Abstract

Overall prognosis for osteosarcoma (OS) is poor despite aggressive treatment options. Limited access to primary tumors, technical challenges in processing OS tissues, and the lack of well-characterized primary cell cultures has hindered our ability to fully understand the properties of OS tumor initiation and progression. In this study, we have isolated and characterized cell cultures derived from four central high-grade human OS samples. Furthermore, we used the cell cultures to study the role of CD49f in OS progression. Recent studies have implicated CD49f in stemness and multipotency of both cancer stem cells and mesenchymal stem cells. Therefore, we investigated the role of CD49f in osteosarcomagenesis. First, single cell suspensions of tumor biopsies were subcultured and characterized for cell surface marker expression. Next, we characterized the growth and differentiation properties, sensitivity to chemotherapy drugs, and anchorage-independent growth. Xenograft assays showed that cell populations expressing CD49f(hi) /CD90(lo) cell phenotype produced an aggressive tumor. Multiple lines of evidence demonstrated that inhibiting CD49f decreased the tumor-forming ability. Furthermore, the CD49f(hi) /CD90(lo) cell population is generating more aggressive OS tumor growth and indicating this cell surface marker could be a potential candidate for the isolation of an aggressive cell type in OSs.

Indexed as

AdolescentAdultAnimalsAntineoplastic AgentsBiomarkers, TumorBone NeoplasmsCell MovementCell ProliferationChildCisplatinDisease ProgressionDoxorubicinDrug Resistance, NeoplasmFemaleHumansIntegrin alpha6Antineoplastic AgentsBiomarkers, TumorCisplatinDoxorubicinIntegrin alpha6Cancer stem cellCD49fintegrinosteosarcomatumor-initiating celltumor progression

Identifiers

PMID24802970
PMCPMC4303148
OpenAlexW2021178817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.